Robert W. Baird assumed coverage on shares of Neoleukin Therapeutics (NASDAQ:NLTX) in a report published on Tuesday, Benzinga reports. The firm issued an outperform rating and a $25.00 target price on the stock.
A number of other research firms have also recently weighed in on NLTX. Piper Sandler upped their price objective on shares of Neoleukin Therapeutics from $28.00 to $30.00 and gave the company an overweight rating in a research report on Wednesday, August 12th. Zacks Investment Research cut shares of Neoleukin Therapeutics from a buy rating to a hold rating in a research report on Wednesday, September 2nd. Canaccord Genuity reissued a buy rating and issued a $20.00 price objective on shares of Neoleukin Therapeutics in a research report on Thursday, June 25th. BidaskClub raised shares of Neoleukin Therapeutics from a sell rating to a hold rating in a research report on Saturday, September 19th. Finally, Mizuho reaffirmed a buy rating and set a $21.00 price target on shares of Neoleukin Therapeutics in a research report on Wednesday, August 12th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Neoleukin Therapeutics has an average rating of Buy and a consensus target price of $21.25.
Shares of NASDAQ NLTX opened at $11.23 on Tuesday. Neoleukin Therapeutics has a 12-month low of $2.53 and a 12-month high of $18.13. The company has a market cap of $468.84 million, a P/E ratio of -3.91 and a beta of 1.01. The company has a current ratio of 20.73, a quick ratio of 20.73 and a debt-to-equity ratio of 0.08. The stock has a fifty day moving average price of $12.41 and a 200 day moving average price of $12.08.
Neoleukin Therapeutics (NASDAQ:NLTX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. On average, sell-side analysts forecast that Neoleukin Therapeutics will post -0.9 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Two Sigma Advisers LP lifted its holdings in Neoleukin Therapeutics by 94.5% in the second quarter. Two Sigma Advisers LP now owns 38,700 shares of the company’s stock worth $642,000 after acquiring an additional 18,800 shares during the last quarter. Nuveen Asset Management LLC bought a new position in Neoleukin Therapeutics in the second quarter worth about $3,458,000. Charles Schwab Investment Management Inc. increased its stake in shares of Neoleukin Therapeutics by 426.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 73,959 shares of the company’s stock valued at $1,228,000 after purchasing an additional 59,902 shares during the period. California State Teachers Retirement System acquired a new stake in shares of Neoleukin Therapeutics in the second quarter valued at approximately $743,000. Finally, Great West Life Assurance Co. Can acquired a new stake in shares of Neoleukin Therapeutics in the second quarter valued at approximately $46,000. 60.22% of the stock is currently owned by hedge funds and other institutional investors.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy.
Featured Article: How to Invest in Stocks with Increasing Dividends
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.